SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) NOVEMBER 12, 2002
------------------
NOVADEL PHARMA INC.
-----------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 000-23399 22-2407152
--------------------------------------------------------------------------
(STATE OR OTHER (COMMISSION (IRS EMPLOYER
JURISDICTION OF FILE NUMBER) IDENTIFICATION NO.)
FORMATION)
31 STATE HIGHWAY 12 FLEMINGTON, NJ 08822
-----------------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (908) 782-3431
--------------
-----------------------------------------------------------
(FORMER NAME OR FORMER ADDRESS, IF CHANGES SINCE LAST REPORT)
ITEM 5. OTHER EVENTS.
------------
On November 12, 2002, Novadel Pharma Inc., a Delaware corporation (the
"Company"), extended the expiration date of its Redeemable Common
Stock Purchase Warrants (the "Warrants") from November 18, 2002 to
November 18, 2003.
The terms of the Warrants that have been extended are identical and
otherwise will remain unchanged. The Warrants are and will continue to allow
the holder thereof to purchase one share of Common Stock of the Company at an
exercise price of $5.80 per share.
Holders of the Warrants need not take any action in connection with the
extension of the expiration date of the Warrants. The existing certificates
will continue to represent the right to acquire shares of the Company's common
stock on the same terms and conditions (other than the
expiration date) as were in effect prior to the extension.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA INFORMATION AND EXHIBITS.
--------------------------------------------------------
(c) Exhibits
99 Press Release dated November 13, 2002.
ITEM 9. REGULATION FD DISCLOSURE.
------------------------
Exhibit 99 hereto sets forth a press release issued by the Company to
report the extension of the Warrants and additional information about the
Company.
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly authorized and caused the undersigned to sign this Report on
the Registrant's behalf.
NOVADEL PHARMA INC.
By: /s/ Harry A. Dugger, III
------------------------
Name: Harry A. Dugger, III
Title: President and Chief Executive
Officer
Dated: November 13, 2002